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Clinical CommunicationsTABLE I. Lymphocyte subsets and immunoglobulin levels at first
assessment of the child
Results Normal valuePartial RAG deficiency in a patient
with varicella infection, autoimmune
cytopenia, and anticytokine antibodiesCD3 152/mL 900-4,500/mL
CD4þ 92.8/mL 500-2,400/mL
CD8þ 32.5/mL 300-1,600/mL
CD4þCD45RAþ 19% >60%
CD19þ 213.8/mL 200-2,100/mL
CD16þ CD 56þ 444.7/mL 100-1,000/mL
IgG 1,997 mg/dL 453-916 mg/dL
IgA 0.01 mg/dL 20-100 mg/dL
IgM 128 mg/dL 19-146 mg/dLVera Goda, MDa, Aniko Malik, MDb, Tibor Kalmar, PhDc,
Zoltan Maroti, PhDc, Bhumika Patel, MDd,
Boglarka Ujhazi, MSd, Krisztian Csomos, PhDd,
Jaime E. Hale, MSe, Karin Chen, MDf, Jacob Bleesing, MDg,
Paolo Palma, MDh, Caterina Cancrini, MD, PhDh,
Anne M. Comeau, PhDe, Gergely Krivan, MD, PhDa, and
Jolan E. Walter, MD PhDd,i
Clinical Implications Combined immunodeﬁciencies may initially present
with herpes virus infections, autoimmune cytopenia, and
antibodies to cytokines. Beyond the assessment of naive
T cells, screen for anticytokine antibodies is useful to
identify an underlying combined immunodeﬁciency
ultimately conﬁrmed by genetic testing.TO THE EDITOR:
Autoimmune cytopenia (AIC) can occur after viral infection as
a comorbid condition with primary immunodeﬁciencies (PIDs).
Patients with PIDs may develop severe complications with acute
viral infections and AIC.1,2 Early detection of an underlying PID
may promote deﬁnitive treatment, such as hematopoietic stem
cell transplantation (HSCT).
Patients with partial defects in severe combined immunode-
ﬁciency (SCID)-associated genes, such as recombination acti-
vating gene (RAG), are increasingly reported with
autoimmunity, such as AIC beyond infections.3,4 The RAG1/2
proteins are essential components of the V(D)J recombination
process that diversiﬁes the repertoires of the T- and B-cell re-
ceptors. RAG1/2 deﬁciency has a broad phenotypic spectrum
including combined immunodeﬁciency with granulomatous
disease and/or autoimmunity (CID-G/AI) where milder
impairment of RAG1/2 recombinase activity results in relatively
preserved T- and B-lymphocyte counts and immunoglobulin
levels; however, naive T-cell counts progressively decrease.5
Therefore, measurement of T-cell receptor excision circles
(TRECs), reﬂecting naive T-cell count, may identify these pa-
tients at birth in asymptomatic stage (via newborn screening) or
later in life in the midst of infectious or autoimmune compli-
cations. However, in countries where newborn screening for
SCID is not available, serological testing with a panel of anti-
cytokine autoantibodies targeting IFN-a, IFN-u, and IL-12 may
serve as a complementary tool to raise suspicion for an under-
lying RAG deﬁciency with CID-G/AI phenotype in a child with
a history of refractory AIC with severe viral infections.3
Hereby we report a 26-month-old female with partial RAG
deﬁciency, nonvaccine strain varicella infection, and severe re-
fractory AIC and discuss our diagnostic approach in Hungary
where newborn screening for SCID is not available.Downloaded for Anonymous User (n/a) at HUNGARY - Szeged Un
For personal use only. No other uses without permission.A previously healthy 26-month-old white female was
referred to our immunology group for immune evaluation of
prolonged varicella infection. The patient had extensive vesic-
ular rash on the entire body and continued to develop new
vesicular eruptions up to 2 weeks after onset of symptoms. No
other organ involvement was noted. Two months after the
onset of varicella, she developed immune thrombocytopenia
(platelet count, 2  109/L), recalcitrant to high-dose intrave-
nous immunoglobulin and pulse glucocorticosteroid treatment.
The family history was negative for consanguinity, PID, and
autoimmunity.
Immune phenotyping was notable for decreased total and
naive T-cell count, but preserved B- and natural killerecell
compartments. Polyclonal gammopathy, low IgA level, and
normal IgM level were also noted (Table I). Lymphocyte pro-
liferation assay revealed low response to PHA (Systéme Inter-
nationale [SI], 3) and concanavalin A (SI, 8), and a low normal
response to pokeweed mitogen (SI, 11) (SI normal value, >10.)
Infection with HIV, EBV, and cytomegalovirus was ruled out by
serologic assay. The patient generated appropriate varicella zoster
antibody response with seroconversion on day 8. (Testing with
Virotech ELISA antievaricella zoster virus IgM positive OD/CO
3.396, IgG positive: OD/CO 1.384, IgA negative.)
Retrospective testing of TRECs from newborn screening
blood spot specimen was undetectable (<252 copies/mL) in
collaboration with the New England Newborn Screening
Program.
Polyclonal gammopathy prompted screening for autoanti-
bodies. There was a borderline positive antinuclear antibody titer
at 1:40. Antiplatelet antibodies were not tested by clinical lab-
oratory testing because this laboratory assay is not available for
routine testing for immune thrombocytopenia in Hungary.
Antibodies against double-stranded deoxyribonucleic acid, anti-
esmooth-muscle antibody, antimitochondrial antibody, anti-
neutrophil cytoplasmic antibody, and antibodies against
cytoplasmic antigens, centromere antigens, and parietal cells were
all negative by clinical laboratory testing. Autoantibodies tar-
geting cytokines IFN-a, IFN-u, and IL-12 were detected by
ELISA (Figure 1).
The patient’s history of prolonged varicella infection with
AIC, reduced naive T-cell compartment, and impaired T-cell
proliferation was concerning for a severe form of PID and1
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FIGURE 1. Anticytokine autoantibodies targeting IFN-a, IFN-u, and IL-12 were detected by ELISA. Our patient had higher levels of
anticytokine autoantibodies than the normal healthy controls. Positive controls are patients (aged 30, 18, and 6 years) with hypomorphic
RAG deficiency and persistence of anticytokine antibodies, as previously described.3
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2 CLINICAL COMMUNICATIONSprompted preparation for emergent allogeneic HSCT. The
combination of clinical and laboratory features with naive T-
cell lymphopenia and the presence of autoantibodies targeting
IFN-a, IFN-u, and IL-12 raised the possibility of RAG
deﬁciency.3
A search for an underlying genetic mutation was initiated
concomitantly with preparation for HSCT. Genomic DNA
separated from peripheral blood samples from the patient and
parents was used for library preparation and sequenced with
Trusight One clinical exome kit (Illumina) on Illumina MiSeq
platform for next-generation sequencing. This clinical exome kit
covers the coding region of 4813 clinically relevant, disease-
associated genes.
Three missense variants in the RAG1 gene were identiﬁed.
We excluded NM_000448.2:c.746A>G (rs3740955) as a
possible causative mutation because it has high minor allele
frequency (MAF, 44.70) in the Exome Aggregation Consortium
database (http://exac.broadinstitute.org). Two rare missense
variants in exon 2 (NM_000448.2:c.1331C>T, rs199474685
with an MAF of 0.0008 and NM_000448.2:c.2974A>G,
rs539590514 with an MAF of 0.000007) were identiﬁed by
next-generation sequencing and conﬁrmed by targeted Sanger
sequencing. Patient was conﬁrmed to have a compound het-
erozygous RAG1 mutation by inheriting RAG1 c.2974A>G
p.Lys992Glu from the mother and RAG1 c.1331C>T
p.Ala444Val from the father. Residual Rag1 recombination ac-
tivity was 9.2% (p.Lys992Glu) and 1.4% (p.Ala444Val), as
measured by an in vitro recombinase assay.6 No mutations were
identiﬁed in the RAG2 gene.
The mutation p.Lys992Glu has previously been reported in
a homozygous and compound heterozygous form in Omenn
syndrome at age 5 to 6 months.7 The mutation p.Ala444Val
has been reported in both homozygous and compound het-
erozygous forms in young infants with the leaky SCID, OmennDownloaded for Anonymous User (n/a) at HUNGARY - Szeged Un
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All patients had B-cell lymphopenia and no history of auto-
immunity. This is in contrast to our previously healthy patient
presenting at age 26 months with varicella infection followed
by severe AIC and laboratory phenotype of preserved B-cell
compartment and polyclonal gammopathy. We postulate that
our patient had polyclonal B-cell activation and AIC secondary
to viral infection. The low naive T-cell compartment, unde-
tectable TRECs, and poor T-cell proliferation are consistent
with deﬁnition of leaky SCID; however, preserved B-cell
lymphocyte count, polyclonal gammopathy, and autoimmune
complications suggest a shift in phenotype to CID-G/AI. Our
patient underwent HSCT with a 10/10 matched unrelated
donor. Thrombocytes engrafted day 43 and CD3þ/CD4þ
reached the normal range on day 129 posttransplant. Patient is
currently 13 months after transplantation with no evidence of
cytopenia.
Regarding the clinical history, our case had some similarities
with 3 additional cases that we previously published.3 The
comparison of cases is listed in Table E1, available in this article’s
Online Repository at www.jaci-inpractice.org. There is close
timing of 2 to 4 months between the onset of viral infection and
AIC with emergence of anticytokine antibodies. These anti-
bodies were absent in young infants with hypomorphic RAG and
absence of infection.3,9
Evaluation of a child with autoimmune cytopenia for CID,
such as our case, can be difﬁcult if lymphocyte immunopheno-
typing is atypical and immunoglobulin levels normal or elevated.
The low number of naive T cells is a key ﬁnding and can be
expedited by using the TREC assay. However, in countries
where TREC screening is not available, such as Hungary, using
autoantibody proﬁling with anticytokine antibody testing may
help to identify those with an underlying combined immuno-
deﬁciency, such as partial RAG deﬁciency, and expedite earlyiversity from ClinicalKey.com by Elsevier on April 26, 2018.
 Copyright ©2018. Elsevier Inc. All rights reserved.
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TABLE E1. Clinical history and laboratory features of patients with partial RAG deficiency and AIC with herpes virus infection
Pt Phenotype Mutation
Live
vaccination
Onset of VZV or
CMV infection
Onset of
autoimmune
cytopenia
Time
diffence
between
infection
and AIC
Age of
diagnosis
of RAG
deficiency
Time
difference
between
AIC and
diagnosis
of RAG
deficiency
Immune
modulation HCT
Age at
testing for
autoantibodies
Anticytokine
antibodies Reference
1 Leaky
SCID
RAG 1
a. R474C
b. K983NfsX9
None VZV—20 mo Coombsþ
AIHA— 21 mo
1 mo 24 mo 3 mo Nonresponsive to
GCSF. Given
high-dose IVIG 1
g/kg/d  2
d without response.
Rituximab starting
at w22 mo  4
doses
2 and 4 y 2 y IFN-a, IFN-u E1,E2
2 CID-G/AI RAG 2
a. G451A
b. M459L
VZV VA-VZV— 13 mo Antineutrophil
antibodyþ
AN— 13 mo
0 m 16 mo 3 mo NA 18 mo 13 mo IFN-a E1
3 Leaky
SCID
RAG 1
a-b. K86fsX33
BCG, MR CMV—7 mo Coombsþ
AIHA— 11 mo
4 mo 13 mo 2 mo High-dose steroid,
high-dose IVIG,
rituximab,
plasmapheresis
18 mo 11 mo IFN-a, IFN-u E1
4 CID-G/AI RAG 2
a. A444V
b. L992G
None VZV—24 mo ITP—26 mo 2 mo 30 mo 4 mo High-dose steroid,
high-dose IVIG
30 mo 28 mo IFN-a, IFN-u,
IL-12
Current
case
GCSF, Granulocyte colony stimulating factor; IFN-a, interferon-alfa; IFN-u, interferon omega; ITP, immune thrombocytopenia; IVIG, intravenous immunoglobulin; NA, not available; VZV, varicella zoster virus.
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